Please enable JavaScript to continue using this application.

Compare $FDMT vs $VSTM | Chartloom

Compare

$FDMT vs $VSTM

4D Molecular Therapeutics Inc · Verastem Inc

FDMT

4D Molecular Therapeutics Inc

VSTM

Verastem Inc

Compare $FDMT vs $VSTM

Comparing 4D Molecular Therapeutics Inc and Verastem Inc

FDMT4D Molecular Therapeutics Inc

VSTMVerastem Inc

FDMT4D Molecular Therapeutics Inc

Market cap

$697M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

50.39x

Rev growth (TTM)

278712.1%

YTD performance

82.1%

52W performance

38.0%

FCF yield

-22.4%

VSTMVerastem Inc

Market cap

$736M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

4.92x

Rev growth (TTM)

3995.7%

YTD performance

15.9%

52W performance

-6.3%

FCF yield

-23.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

FDMT

VSTM

Detailed metrics comparison

FDMT

4D Molecular Therapeutics Inc

VSTM

Verastem Inc

Market Cap

FDMT$697M

VSTM$736M

Enterprise Value

FDMT$646M

VSTM$682M

Price

FDMT$13.33

VSTM$8.38

P/E Ratio

FDMTN/A

VSTMN/A

P/S Ratio

FDMT7.57x

VSTM8.41x

EV/Sales

FDMT7.02x

VSTM7.79x

EV/EBITDA

FDMT0.00x

VSTM0.00x

P/B Ratio

FDMT1.85x

VSTM14.07x

P/FCF Ratio

FDMTN/A

VSTMN/A

EV/FCF

FDMT-4.13x

VSTM-3.97x

PEG Ratio

FDMTN/A

VSTMN/A

Forward P/E (NTM)

FDMTN/A

VSTMN/A

Forward P/S (NTM)

FDMT50.39x

VSTM4.92x

Revenue (TTM)

FDMT$92M

VSTM$88M

Revenue Growth (YoY)

FDMT278712.1%

VSTM3995.7%

Forward Rev Growth

FDMT40.6%

VSTM61.6%

Gross Margin (TTM)

FDMT0.0%

VSTM87.6%

Operating Margin (TTM)

FDMT0.0%

VSTM0.0%

EBITDA Margin (TTM)

FDMT-208.8%

VSTM-181.3%

Net Margin (TTM)

FDMT-194.7%

VSTM-231.6%

FCF Margin (TTM)

FDMT-169.9%

VSTM-196.3%

Net Income (TTM)

FDMT$-179M

VSTM$-203M

FCF (TTM)

FDMT$-156M

VSTM$-172M

EPS (TTM)

FDMT-$2.55

VSTM-$2.02

ROE (TTM)

FDMT-4133.0%

VSTM-16540.0%

ROA (TTM)

FDMT-3590.0%

VSTM-9454.0%

ROIC (TTM)

FDMT-4087.0%

VSTM-7104.0%

Cash

FDMT$70M

VSTM$136M

Debt

FDMT$20M

VSTM$82M

Net Cash/Debt

FDMT$51M

VSTM$55M

Current Ratio (TTM)

FDMT8.03x

VSTM2.25x

Quick Ratio (TTM)

FDMT7.68x

VSTM2.12x

Debt/Equity (TTM)

FDMT0.05x

VSTM1.63x

Debt/Assets (TTM)

FDMT0.0%

VSTM0.0%

Interest Coverage (TTM)

FDMTN/A

VSTMN/A

Net Debt/EBITDA (TTM)

FDMT0.00x

VSTM0.00x

Beta

FDMT2.90

VSTM0.58

52W Performance

FDMT38.0%

VSTM-6.3%

YTD Performance

FDMT82.1%

VSTM15.9%

% from 52W High

FDMT-21.3%

VSTM-22.6%

% from 52W Low

FDMT91.5%

VSTM144.3%

Asset Turnover (TTM)

FDMT0.18x

VSTM0.41x

FCF Yield (TTM)

FDMT-22.4%

VSTM-23.3%

Earnings Yield (TTM)

FDMT-25.7%

VSTM-27.5%

Dividend Yield (TTM)

FDMTN/A

VSTMN/A

Rule of 40

FDMT278,542.3

VSTM3,799.4

EV/GP/RG

FDMTN/A

VSTM0.13

Ticker research

View FDMT research View VSTM research

Metric	FDMT 4D Molecular Therapeutics Inc	VSTM Verastem Inc
Market & Valuation
Market Cap	$697M	$736M
Enterprise Value	$646M	$682M
Price	$13.33	$8.38
P/E Ratio	N/A	N/A
P/S Ratio	7.57x	8.41x
EV/Sales	7.02x	7.79x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.85x	14.07x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.13x	-3.97x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	50.39x	4.92x
Revenue & Growth
Revenue (TTM)	$92M	$88M
Revenue Growth (YoY)	278712.1%	3995.7%
Forward Rev Growth	40.6%	61.6%
Profitability
Gross Margin (TTM)	0.0%	87.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-208.8%	-181.3%
Net Margin (TTM)	-194.7%	-231.6%
FCF Margin (TTM)	-169.9%	-196.3%
Net Income (TTM)	$-179M	$-203M
FCF (TTM)	$-156M	$-172M
EPS (TTM)	-$2.55	-$2.02
ROE (TTM)	-4133.0%	-16540.0%
ROA (TTM)	-3590.0%	-9454.0%
ROIC (TTM)	-4087.0%	-7104.0%
Financial Health
Cash	$70M	$136M
Debt	$20M	$82M
Net Cash/Debt	$51M	$55M
Current Ratio (TTM)	8.03x	2.25x
Quick Ratio (TTM)	7.68x	2.12x
Debt/Equity (TTM)	0.05x	1.63x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.90	0.58
52W Performance	38.0%	-6.3%
YTD Performance	82.1%	15.9%
% from 52W High	-21.3%	-22.6%
% from 52W Low	91.5%	144.3%
Efficiency & Yields
Asset Turnover (TTM)	0.18x	0.41x
FCF Yield (TTM)	-22.4%	-23.3%
Earnings Yield (TTM)	-25.7%	-27.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	278,542.3	3,799.4
EV/GP/RG	N/A	0.13
Ticker research	View FDMT research	View VSTM research

Valuation

P/S Ratio

FDMT

7.57x

VSTM

8.41x

EV/FCF

FDMT

-4.13x

VSTM

-3.97x

Growth & revenue

Revenue Growth TTM

FDMT

278712.1%

VSTM

3995.7%

Forward Revenue Growth

VSTM

61.6%

FDMT

40.6%

Profitability & performance

Gross Margin

VSTM

87.6%

FDMT

0.0%

ROE

FDMT

-4133.0%

VSTM

-16540.0%

FCF Yield %

FDMT

-22.4%

VSTM

-23.3%

52-Week Performance

FDMT

38.0%

VSTM

-6.3%

Detailed metrics comparison

FDMT

4D Molecular Therapeutics Inc

VSTM

Verastem Inc

Market Cap

FDMT$697M

VSTM$736M

Enterprise Value

FDMT$646M

VSTM$682M

Price

FDMT$13.33

VSTM$8.38

P/E Ratio

FDMTN/A

VSTMN/A

P/S Ratio

FDMT7.57x

VSTM8.41x

EV/Sales

FDMT7.02x

VSTM7.79x

EV/EBITDA

FDMT0.00x

VSTM0.00x

P/B Ratio

FDMT1.85x

VSTM14.07x

P/FCF Ratio

FDMTN/A

VSTMN/A

EV/FCF

FDMT-4.13x

VSTM-3.97x

PEG Ratio

FDMTN/A

VSTMN/A

Forward P/E (NTM)

FDMTN/A

VSTMN/A

Forward P/S (NTM)

FDMT50.39x

VSTM4.92x

Revenue (TTM)

FDMT$92M

VSTM$88M

Revenue Growth (YoY)

FDMT278712.1%

VSTM3995.7%

Forward Rev Growth

FDMT40.6%

VSTM61.6%

Gross Margin (TTM)

FDMT0.0%

VSTM87.6%

Operating Margin (TTM)

FDMT0.0%

VSTM0.0%

EBITDA Margin (TTM)

FDMT-208.8%

VSTM-181.3%

Net Margin (TTM)

FDMT-194.7%

VSTM-231.6%

FCF Margin (TTM)

FDMT-169.9%

VSTM-196.3%

Net Income (TTM)

FDMT$-179M

VSTM$-203M

FCF (TTM)

FDMT$-156M

VSTM$-172M

EPS (TTM)

FDMT-$2.55

VSTM-$2.02

ROE (TTM)

FDMT-4133.0%

VSTM-16540.0%

ROA (TTM)

FDMT-3590.0%

VSTM-9454.0%

ROIC (TTM)

FDMT-4087.0%

VSTM-7104.0%

Cash

FDMT$70M

VSTM$136M

Debt

FDMT$20M

VSTM$82M

Net Cash/Debt

FDMT$51M

VSTM$55M

Current Ratio (TTM)

FDMT8.03x

VSTM2.25x

Quick Ratio (TTM)

FDMT7.68x

VSTM2.12x

Debt/Equity (TTM)

FDMT0.05x

VSTM1.63x

Debt/Assets (TTM)

FDMT0.0%

VSTM0.0%

Interest Coverage (TTM)

FDMTN/A

VSTMN/A

Net Debt/EBITDA (TTM)

FDMT0.00x

VSTM0.00x

Beta

FDMT2.90

VSTM0.58

52W Performance

FDMT38.0%

VSTM-6.3%

YTD Performance

FDMT82.1%

VSTM15.9%

% from 52W High

FDMT-21.3%

VSTM-22.6%

% from 52W Low

FDMT91.5%

VSTM144.3%

Asset Turnover (TTM)

FDMT0.18x

VSTM0.41x

FCF Yield (TTM)

FDMT-22.4%

VSTM-23.3%

Earnings Yield (TTM)

FDMT-25.7%

VSTM-27.5%

Dividend Yield (TTM)

FDMTN/A

VSTMN/A

Rule of 40

FDMT278,542.3

VSTM3,799.4

EV/GP/RG

FDMTN/A

VSTM0.13

Ticker research

View FDMT research View VSTM research

Metric	FDMT 4D Molecular Therapeutics Inc	VSTM Verastem Inc
Market & Valuation
Market Cap	$697M	$736M
Enterprise Value	$646M	$682M
Price	$13.33	$8.38
P/E Ratio	N/A	N/A
P/S Ratio	7.57x	8.41x
EV/Sales	7.02x	7.79x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.85x	14.07x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.13x	-3.97x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	50.39x	4.92x
Revenue & Growth
Revenue (TTM)	$92M	$88M
Revenue Growth (YoY)	278712.1%	3995.7%
Forward Rev Growth	40.6%	61.6%
Profitability
Gross Margin (TTM)	0.0%	87.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-208.8%	-181.3%
Net Margin (TTM)	-194.7%	-231.6%
FCF Margin (TTM)	-169.9%	-196.3%
Net Income (TTM)	$-179M	$-203M
FCF (TTM)	$-156M	$-172M
EPS (TTM)	-$2.55	-$2.02
ROE (TTM)	-4133.0%	-16540.0%
ROA (TTM)	-3590.0%	-9454.0%
ROIC (TTM)	-4087.0%	-7104.0%
Financial Health
Cash	$70M	$136M
Debt	$20M	$82M
Net Cash/Debt	$51M	$55M
Current Ratio (TTM)	8.03x	2.25x
Quick Ratio (TTM)	7.68x	2.12x
Debt/Equity (TTM)	0.05x	1.63x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.90	0.58
52W Performance	38.0%	-6.3%
YTD Performance	82.1%	15.9%
% from 52W High	-21.3%	-22.6%
% from 52W Low	91.5%	144.3%
Efficiency & Yields
Asset Turnover (TTM)	0.18x	0.41x
FCF Yield (TTM)	-22.4%	-23.3%
Earnings Yield (TTM)	-25.7%	-27.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	278,542.3	3,799.4
EV/GP/RG	N/A	0.13
Ticker research	View FDMT research	View VSTM research